As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, FDA granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy.
MD Anderson and Texas Children’s Hospital have entered into a collaboration to build a $1 billion pediatric cancer hospital. The hospital, tentatively slated to open in 2031 or 2032, is on track to become one of the largest pediatric cancer hospitals in the world.
